Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in children and adolescents with moderately to severely active ulcerative colitis
NL-OMON59154Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of mirikizumab in autoimmune colitis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Modified Mayo Score clinical remission at Week 52 among Week 12 clinical responders. Started May 2024; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON59154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59154.